Jane Larkindale, DPhil

Title: VP of Clinical Science PepGen

Bio: Jane Larkindale serves as the Vice President of Clinical Science at PepGen. Jane has dedicated the past 15 years of her career to accelerating therapy development for rare diseases, with a focus on neuromuscular diseases. Prior to PepGen, Jane was Executive Director at Critical Path Institute where she conceived of and led the Rare Disease Cures Accelerator, Data and Analytics Platform and multiple disease specific consortia. Prior to the Critical Path Institute, Jane held the position of Vice President of Research Development at Friedreich’s Ataxia Research Alliance and the Muscular Dystrophy Association. Jane is a molecular biologist by training, having completed her D.Phil. (Ph.D.) in the Department of Plant Sciences at Oxford University, which she attended on a Rhodes Scholarship.

2023 FUTURES: RNA targeted Therapeutics Sessions Part 2

Continued updates from relevant companies in the space. These presentations will be followed by a moderated Q&A opportunity.

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

Jane Larkindale, DPhil

VP of Clinical Science PepGen

Dania Porco, MS, MBA, CGC

Director in Clinical Science BioMarin Pharmaceutical Inc.

Michael Tillinger, MD

VP of Clinical Development Wave Life Sciences